Industry

Pharmaceuticals

Developers of branded and generic drugs. Value creation rests on R&D pipelines, patent lifecycles, regulatory approvals and pricing power versus payers.

Total Companies
1 294
Company Intrinsic Valuation Profitability Score Solvency Score Market Cap
Eli Lilly and Co
NYSE:LLY
Loading...
62% Overvalued
76 / 100
68 / 100
$984.9B
Dechra Pharmaceuticals PLC
LSE:DPH
Loading...
N/A
39 / 100
50 / 100
$591.9B
Johnson & Johnson
NYSE:JNJ
Loading...
19% Overvalued
63 / 100
57 / 100
$525.1B
Roche Holding AG
SIX:ROG
Loading...
23% Undervalued
64 / 100
63 / 100
$346.1B
AstraZeneca PLC
LSE:AZN
Loading...
13% Undervalued
39 / 100
46 / 100
$279B
Novartis AG
SIX:NOVN
Loading...
1% Overvalued
73 / 100
70 / 100
$276.7B
Merck & Co Inc
NYSE:MRK
Loading...
9% Undervalued
66 / 100
70 / 100
$272.2B
Novo Nordisk A/S
CSE:NOVO B
Loading...
24% Undervalued
75 / 100
71 / 100
$267.5B
Pfizer Inc
NYSE:PFE
Loading...
10% Undervalued
51 / 100
45 / 100
$145.1B
Sanofi SA
PAR:SAN
Loading...
51% Undervalued
57 / 100
45 / 100
$112B
Bristol-Myers Squibb Co
NYSE:BMY
Loading...
22% Undervalued
60 / 100
41 / 100
$110.4B
GlaxoSmithKline PLC
LSE:GSK
Loading...
10% Undervalued
39 / 100
47 / 100
$96.4B
Chugai Pharmaceutical Co Ltd
TSE:4519
Loading...
46% Overvalued
70 / 100
93 / 100
$85.8B
Merck KGaA
XETRA:MRK
Loading...
12% Undervalued
51 / 100
57 / 100
$64B
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Loading...
17% Overvalued
64 / 100
87 / 100
$57.5B
Ucb SA
XBRU:UCB
Loading...
2% Overvalued
56 / 100
76 / 100
$57.1B
Zoetis Inc
NYSE:ZTS
Loading...
3% Undervalued
72 / 100
65 / 100
$54.4B
A
Aspen Pharmacare Holdings Ltd
JSE:APN
Loading...
N/A
34 / 100
41 / 100
$51.5B
Takeda Pharmaceutical Co Ltd
TSE:4502
Loading...
Fairly Valued
45 / 100
37 / 100
$50.5B
Bayer AG
XETRA:BAYN
Loading...
60% Undervalued
41 / 100
29 / 100
$48.8B
Load More